Chronic Kidney Disease Trial, Recruiting NCT07554469 Sponsor: Bayer Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT07554469
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their written agreement to take part in the study.
  • Men or women aged 18 years or older.
  • People who have chronic kidney disease linked to type 2 diabetes, along with higher-than-normal levels of a protein called albumin in their urine (a urine test result above 30 mg/g).
  • People who have been started on a medication called finerenone in routine medical care, following the approved prescribing guidelines, within the 2 months before joining the study.

Who may not be able to join:

  • People whose kidneys are functioning below a certain level, based on a measure called eGFR being lower than 25 mL/min/1.73 m² (confirm with trial site).
  • People with severe liver problems.
  • People who have been diagnosed with a type of heart failure where the heart pumps weakly (known as HFrEF) and who still have ongoing symptoms.
  • People with a confirmed kidney disease that is not caused by diabetes, including a significant narrowing of the arteries supplying the kidneys.
  • People whose blood pressure is not well controlled — specifically, a sitting systolic reading of 160 mmHg or higher, or a diastolic reading of 100 mmHg or higher, at the time of joining.
  • People who are currently taking certain medications — including eplerenone, spironolactone, any renin inhibitor, or a potassium-sparing water tablet — unless those medications were stopped at least 4 weeks before joining the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+)1-888-84 22937

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
26 May 2026
Est. completion
30 April 2029

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Percentage of patients who show an improvement in the Klinrisk model score after 24 months of treatment with finerenone.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov